Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how ...

Single-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment ...

Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...

Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond ...

As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...

Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its ...

The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...

The termination ends a cardiometabolic RNA-editing partnership that was paused for 12 months, closing out a deal under which ...

Accelerated approval of subcutaneous Rybrevant Faspro (amivantamab) based on a 42% response rate in 102 patients; a phase 3 confirmatory trial is under way.

When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for ...